Skip to content
  • BiotechReality JobFinder
  • Market Analysis
  • Publish on BiotechReality
  • linkedin
  • facebook
  • instagram
  • twitter
BiotechReality
BiotechReality – Information Intelligence System for Biopharma
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
Popular
#FDA #Eli Lilly and Company #Johnson&Johnson #Clinical Data #Cancer #FDA Approval #Novo Nordisk #Pfizer

Editor's Desk

Healthcare & Pharmaceuticals Clinical Trials News

Merck Announces Positive Results of Phase 3 Trials for Their HIV-1 Investigational Two-Drug Regimen Doravirine/Islatravir

  • By Editor's Desk
  • 13 March 2025
Merck MSD

Islatravir, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), inhibits HIV-1 replication through a variety of mechanisms

Tagged HIV, Investigational Drug, Merck & Co
Healthcare & Pharmaceuticals Research

Researchers Developed a More Affordable, Lower-risk Polio Vaccine

  • By Editor's Desk
  • 12 March 2025
vaccine vial image

The current inactivated polio vaccine (IPV), which uses a destroyed form of the poliovirus to trigger an immune system response

Tagged Polio, Polio Vaccine
Clinical Trials Cancer Healthcare & Pharmaceuticals News

Pfizer With Arvinas Announced Positive Results of Phase 3 VERITAC-2 Clinical Trial for Advanced or Metastatic Breast Cancer

  • By Editor's Desk
  • 11 March 2025
pfizer news

At the time of the analysis, less than 25% of the necessary number of events had taken place, indicating that overall survival was not mature.

Tagged Pfizer, VERITAC
Clinical Trials Healthcare & Pharmaceuticals News Weight-loss Drugs

Novo Nordisk’s CagriSema for Obesity and Type 2 Diabetes Shows Superior Results in REDEFINE 2 Trial

  • By Editor's Desk
  • 10 March 2025
novo nordisk

CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.

Tagged CagriSema, Novo Nordisk, REDEFINE
Healthcare & Pharmaceuticals Clinical Trials

Johnson & Johnson Discontinued VENTURA Drug Development Program

  • By Editor's Desk
  • 8 March 2025
JohnsonAndJohnson

The Phase 3 VENTURA research study, which was assessing aticaprant as an adjunctive treatment for major depressive disorder (aMDD), has been discontinued by Johnson & [Read More…]

Tagged Johnson&Johnson, VENTURA Drug Development
Healthcare & Pharmaceuticals Research

Over-the-counter Painkillers Were Associated With Better Concussion Recovery

  • By Editor's Desk
  • 7 March 2025
Over-the-counter Painkillers

The study merely demonstrates a connection rather than proving that painkillers enhance concussion recovery.

Tagged OTC, Painkillers
Regulatory Healthcare & Pharmaceuticals News

Roche’s Supplemental Biologics License Application of Gazyva/Gazyvaro (Obinutuzumab) for The Treatment of Lupus Nephritis Accepted by U.S. FDA

  • By Editor's Desk
  • 6 March 2025
Roche

In a randomized phase III study, Gazyva®/Gazyvaro® is the only anti-CD20 monoclonal antibody that shows a full renal response benefit.

Tagged BLA, FDA, Hoffmann-La Roche, Obinutuzumab
Anti-obesity Drugs Business News

AbbVie Enters Into the Obesity Drug Market With a License Agreement

  • By Editor's Desk
  • 5 March 2025
AbbVie

GUB014295 is a calcitonin and amylin receptor-specific agonist that may be a long-acting amylin analog.

Tagged AbbVie, Anti-obesity drugs, Obesity Drug Market
Clinical Trials News

BEACON-IPF Clinical Trial for Idiopathic Pulmonary Fibrosis Discontinued With Available Results

  • By Editor's Desk
  • 4 March 2025
pliant therapeutics

The BEACON-IPF Phase 2b trial, which was assessing bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), has been discontinued by Pliant Therapeutics, Inc. after a [Read More…]

Tagged BEACON-IPF, Phase 2 Trials, Pliant Therapeutics
Healthcare & Pharmaceuticals News

“Healthy Skepticism” A New Ad Campaign from Lilly Against Compounded Drugs

  • By Editor's Desk
  • 2 March 2025
Eli Lilly and Company Ad campaign

Two blockbuster weight loss drugs including Lilly’s Zepbound were in U.S. FDA’s drugs shortage list.

Tagged Ad Campaign, Eli Lilly and Company, US FDA Shortage List

Posts navigation

← Older Posts
→ Newer Posts
Advertisement

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Autoimmune Diseases
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biologics
  • Biosimilars
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • CDMO
  • Cell Biology
  • Clinical Data
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • CRDMO
  • CRO
  • Cybersecurity
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Legal and Patent Affairs
  • Life Sciences
  • Machine Learning
  • Manufacturing
  • Medical Devices
  • Mental Health
  • Merger & Acquisitions
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Rare Diseases
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
Regulatory Approval Healthcare & Pharmaceuticals News

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

18 July 202617 July 2026
Editor's Desk
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
Regulatory Approval Healthcare & Pharmaceuticals News

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

17 July 202617 July 2026
Editor's Desk
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
Merger & Acquisitions Business Healthcare & Pharmaceuticals

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

16 July 202616 July 2026
Editor's Desk
Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook
Business Healthcare & Pharmaceuticals News

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

15 July 202616 July 2026
Editor's Desk
Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment
Regulatory Approval Healthcare & Pharmaceuticals News Oncology

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

15 July 202615 July 2026
Editor's Desk
AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement
Merger & Acquisitions Healthcare & Pharmaceuticals News Oncology

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement

14 July 202615 July 2026
Editor's Desk
Advertisement
BiotechReality JobFinder

  • Quality Specialist – Thermo Fisher Scientific
    17 July 2026
  • HSE Specialist – Novartis
    17 July 2026
  • Field Application Specialist – Sartorius
    14 July 2026
  • Regulatory Professional – Novo Nordisk
    12 July 2026
  • Senior Biotechnologist – Sanofi
    10 July 2026

BiotechReality Shots Weekly Newsletter

Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
SciRealityPress BiotechReality

A SciRealityPress Associate

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2026
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
  • linkedin
  • facebook
  • instagram
  • twitter